STAAR Reports 6 Percent Increase in Net Sales in Q1-2017

May 12, 2017: By Jon Swedien

STAARSTAAR Surgical had net sales of $20.4 million in Q1-2017, a 6 percent increase over its Q1-2016 net sales, the company reported May 3.

Net sales of STAAR’s Visian Implantable Collamer Lens (ICL) were up 16 percent for Q1-2017 compared with the same quarter in 2016, according to the Monrovia, California, company.

The number of ICLs units sold was up 20 percent for Q1-2017 compared with Q1-2016.

STAAR’s sales for ICLs grew 65 percent in Canada, 65 percent in Japan, and 45 percent in China in Q1-2017 compared with Q1-2016, the company said.

The company’s IOL sales were down 9 percent in Q1-2017 compared with Q1-2016, while the number of units sold was flat. Injector parts dropped 54 percent.

STAAR said it anticipates flat to declining growth for IOL sales in 2017 with the discontinuation of its US silicone IOL business.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022